Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) Net Margin: 2018-2025

Historic Net Margin for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to 21,345.45%.

  • Cidara Therapeutics' Net Margin rose 2240671.00% to 21,345.45% in Q1 2025 from the same period last year, while for Mar 2025 it was -170.13%, marking a year-over-year decrease of 15521.00%. This contributed to the annual value of 36.39% for FY2024, which is 2716.00% up from last year.
  • Cidara Therapeutics' Net Margin amounted to 21,345.45% in Q1 2025, which was up 2,048.06% from 993.71% recorded in Q2 2024.
  • Cidara Therapeutics' 5-year Net Margin high stood at 21,345.45% for Q1 2025, and its period low was -1,061.25% during Q1 2024.
  • Moreover, its 3-year median value for Net Margin was 44.76% (2023), whereas its average is 3,058.97%.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by 107,314bps in 2024, then soared by 2,240,671bps in 2025.
  • Over the past 5 years, Cidara Therapeutics' Net Margin (Quarterly) stood at -600.11% in 2021, then surged by 46,920bps to -130.90% in 2022, then surged by 17,566bps to 44.76% in 2023, then spiked by 79,874bps to 993.71% in 2024, then spiked by 2,240,671bps to 21,345.45% in 2025.
  • Its Net Margin was 21,345.45% in Q1 2025, compared to 993.71% in Q2 2024 and -1,061.25% in Q1 2024.